Level Bio ABFRA:4MB +8.00%23 Market Cap is €1.60 Mil as of Jul. 09, 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 93.58% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Level Bio AB's share price for the quarter that ended in Mar. 2026 was €0.018. Level Bio AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 68.40 Mil. Therefore, Level Bio AB's market cap for the quarter that ended in Mar. 2026 was €1.23 Mil.
Level Bio AB's quarterly market cap
declined
from Sep. 2025 (€1.71 Mil) to Dec. 2025 (€1.20 Mil) but then
increased
from Dec. 2025 (€1.20 Mil) to Mar. 2026 (€1.23 Mil).
Level Bio AB's annual market cap
declined
from Dec. 2023 (€2.05 Mil) to Dec. 2024 (€0.96 Mil) but then
increased
from Dec. 2024 (€0.96 Mil) to Dec. 2025 (€1.20 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Level Bio AB's Enterprise Value for Today is €1.56 Mil.
Level Bio AB (FRA:4MB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Level Bio AB Market Cap Related Terms
Level Bio AB Market Cap Historical Data
* Premium members only.
The historical data trend for Level Bio AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Level Bio AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Level Bio AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Level Bio AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Bio AB (FRA:4MB) has a Market Cap of €1.60 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Level Bio AB and its competitors. According to the industry distribution chart, Level Bio AB ranks #204 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 93.6%.
Is Level Bio AB's Market Cap too high?
Level Bio AB's current Market Cap is €1.60 Mil. Based on the distribution chart, Level Bio AB ranks #204 out of 218 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #204 out of 218 companies for Market Cap. This places Level Bio AB in the lower half of its industry. The industry median Market Cap is 58.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 58.64, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 58.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current Market Cap is €1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Market Cap of €1.60 Mil. The current Market Cap is €1.60 Mil. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Market Cap is €1.60 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
